Control of human and animal platelet aggregation by a new prostacyclin analog.

P. Maderna, S. Colli, C. Sirtori, E. Tremoli, R. Paoletti

Research output: Contribution to journalArticle

Abstract

The in vitro effects of ZK 36 374, a new chemically stable prostacyclin (PGI2) analog, on platelet aggregation were studied and compared to those of PGI2. Significantly lower concentrations of ZK 36 374, versus prostacyclin, were required to inhibit collagen and epinephrine-induced aggregation in human platelet-rich plasma. In contrast, in rat and rabbit platelet rich plasma, PGI2 was more effective than ZK 36 374 in inhibiting the aggregation elicited by ADP and collagen. It is concluded that ZK 36 374 is a potent antiaggregatory compound and may be useful in the prevention of cardiovascular disorders.

Original languageEnglish
Pages (from-to)363-369
Number of pages7
JournalAdvances in prostaglandin, thromboxane, and leukotriene research
Volume13
Publication statusPublished - 1985

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Control of human and animal platelet aggregation by a new prostacyclin analog.'. Together they form a unique fingerprint.

  • Cite this